º» Çѳ²´ëÇб³-BTCI ±³À°¼¾ÅÍ´Â 21¼¼±â Çѱ¹ BT(Biopharmaceutical Technology)»ê¾÷ÀÇ ÁßÈïÀ» À§ÇØ ¼¼°è
56°³±¹°ú ¿¬°á,
1,200¿©°³ÀÇ »ý»êÇ°À» °øÀ¯ÇÏ´Â ¹Ì±¹ Promega»ç¿Í Çѳ²´ëÇб³°¡ °øµ¿À¸·Î ¹Ì±¹ÀÇ Ã·´Ü
»ý¸í°øÇÐ
±³À°¤ý¿¬±¸ ÇÁ·Î±×·¥À» ¿î¿µÇÏ¿© Çѱ¹³» Áߤý°í¤ý´ëÇлý ¹× ±³»ç¿Í
BT(Biopharmaceutical Technology)°ü·Ã ¿¬±¸¿øÀ» ±³À°ÇÏ°í
¾Æ¿ï·¯ Çѱ¹ ¹ÙÀÌ¿À»ê¾÷ÀÇ ¿¬±¸¿ª·® °È¿¡
±â¿©ÇÏ°íÀÚ ÇÕ´Ï´Ù.
Çѳ²´ëÇб³-BTCI ±³À°¼¾ÅÍ ¸í¿¹¿øÀå
Karin Borgh, Ph.D.
- Çö) Çѳ²´ëÇб³-BTCI ±³À°¼¾ÅÍ ¸í¿¹¿øÀå
- Çö) Executive Director, BioPharmaceutical Technology Center Institute
21¼¼±â´Â °úÇбâ¼úÀÌ ±¹°¡ °æÀï·ÂÀÇ Ã´µµÀÓÀ» ÀνÄÇÏ°í ¿ì¼öÇÑ °úÇбâ¼ú Àη¾缺¿¡ Èû½á¾ßÇÏ´Â ½Ã´ëÀû »óȲ¿¡ Á÷¸éÇÏ°í ÀÖ½À´Ï´Ù. Çѳ²´ëÇб³-BTCI ±³À°¼¾ÅÍ´Â ¿ì¸®³ª¶ó °úÇбâ¼úÀÇ ¸ÞÄ«ÀÎ ´ë´ö¹ë¸®¿¡ À§Ä¡ÇÑ Çѳ²´ëÇб³(´ë´öÄ·ÆÛ½º)¿Í ¹Ì±¹ Wisconsin Madison¿¡ ¼ÒÀçÇÏ´Â ¼¼°èÀûÀÎ »ý¸í°øÇÐȸ»ç Promega»çÀÇ ±³À°¡¤¿¬±¸ ±â°üÀÎ BTCI°¡ °øµ¿À¸·Î 2005³â¿¡ ¼³¸³ÇÑ Àü¹® BT(Biopharmaceutical Technology) Àη¾缺 ±³À°±â°üÀÔ´Ï´Ù. º» ¿ø¿¡¼´Â ¹Ì±¹ÀÇ BTCIÀÇ ÇÁ·Î±×·¥À» Çѱ¹ ±³À°½ÇÁ¤¿¡ ¸Â°Ô ¼³°èÇÏ¿© Áö¿ª BT(Biopharmaceutical Technology) »ç¾÷ À°¼º°ú Çлý »ý¸í°øÇÐ ±³À°¿¡ °øÇåÇÏ°í ÀÖ½À´Ï´Ù.
- Çб³ ±³À°°úÁ¤¿¡¼ ºÎÁ·ÇÑ ½ÇÇè¤ýüÇè¤ýŽ±¸ Áß½É(Hands on ½Ç½À)ÀÇ Ã¢ÀÇ°úÇÐ ÇÁ·Î±×·¥À» Á¦°øÇÏ¿©
°úÇÐÀÇ »ýÈ°È ½ÇÇö
- ÇлýµéÀÌ ½±°í Àç¹ÌÀÖ°Ô »ý¸í°øÇÐÀ» Á¢ÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÏ¿© »ý¸í°øÇп¡ ´ëÇÑ Èï¹Ì¿Í ÀÌÇصµ
Á¦°í ¹× °úÇРģÈÀû ±â¹Ý Á¶¼º
- âÀÇÀûÀÎ ¹Ì·¡ ÀÎÀçÀ°¼ºÀ» À§ÇÑ Àڳ౳À° ¿ª·® °È
- ±¹°¡ BT(Biopharmaceutical Technology) »ê¾÷ ±â¹Ý Á¶¼º ¹× Áö¿ª BT(Biopharmaceutical Technology) »ê¾÷
µ¿·Â âÃâÀ» ¸ñÇ¥·Î Áö¿ª »ý¸í°úÇÐ ÀÎÀç ¾ç¼º¿¡ ±â¿©ÇÏ°íÀÚ ÇÔ
Çѳ²´ëÇб³-BTCI ±³À°¼¾ÅÍÀå